Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
188
-
Total 13F shares, excl. options
-
126M
-
Shares change
-
+522K
-
Total reported value, excl. options
-
$277M
-
Value change
-
+$4.31M
-
Put/Call ratio
-
0.83
-
Number of buys
-
76
-
Number of sells
-
-69
-
Price
-
$2.20
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q4 2024
232 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2024.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 188 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 126M shares
of 207M outstanding shares and own 60.74% of the company stock.
Largest 10 shareholders include WASATCH ADVISORS LP (24.5M shares), BlackRock, Inc. (14.2M shares), VANGUARD GROUP INC (11.7M shares), Bellevue Group AG (9.94M shares), MORGAN STANLEY (6.31M shares), Two Seas Capital LP (6.23M shares), STATE STREET CORP (4.5M shares), GEODE CAPITAL MANAGEMENT, LLC (4.34M shares), TWO SIGMA ADVISERS, LP (3.62M shares), and TWO SIGMA INVESTMENTS, LP (3.54M shares).
This table shows the top 188 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.